Nerviano Italy, 11 September 2023 – Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that Alberto Ocana PhD, has joined the Global Clinical Development Team as Global Clinical Lead, effective immediately. In this pivotal role, Alberto will spearhead the company’s efforts to drive innovation, enhance patient outcomes, and strengthen our global partnerships.
Alberto joins with extensive experience in preclinical research and early drug development and more than 15 years’ experience in clinical development and immune oncology. He has worked as principal investigator and Co-PI in many Phase I studies. Alberto’s most recent position is Chief Medical Officer at CancerAppy, a drug discovery company based on artificial intelligence and Strategic Global Director, Early clinical Development at Worldwide Clinical Trials – CRO. He has previously been leading Global program clinical development in Servier. With his extensive background and a proven track record of leadership, he will be a valuable asset in shaping the future of NMS and the advancement of medical science together with the team.
Among his academic experiences, Alberto has been Head experimental therapeutics unit at Hospital Clinico San Carlos in Madrid and Honorific Professor at Universidad Complutense de Madrid. Alberto has an extensive publication history in the field.
Link: 20221031-Global Clinical Lead-Final
from NMSGroup
